Unity Biotechnology, Inc.
UBX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.02 | 0.01 | 0.03 |
| FCF Yield | -126.99% | -130.12% | -196.52% | -55.53% |
| EV / EBITDA | -1.29 | -0.96 | -1.65 | -1.93 |
| Quality | ||||
| ROIC | -96.71% | -72.87% | -46.67% | -48.09% |
| Gross Margin | 0.00% | 0.00% | -823.73% | 39.80% |
| Cash Conversion Ratio | 0.80 | 0.97 | 0.85 | 0.74 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | – | – |
| Free Cash Flow Growth | 43.76% | 27.43% | -12.97% | 42.70% |
| Safety | ||||
| Net Debt / EBITDA | -0.64 | -0.19 | -0.97 | -0.44 |
| Interest Coverage | 0.00 | 0.00 | -16.18 | -17.84 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -9.28 | 0.00 |
| Cash Conversion Cycle | -419.73 | -25.57 | 24.41 | -251.57 |